Abstracts tagged "giant cell arteritis"

Abstract Number: 2648 • ACR Convergence 2024
Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Vicente Aldasoro¹, Vicky Betech-Antar², Santos Castañeda³, Eugenio De Miguel⁴, Juan José Rosales⁵ and Maria Jose García Velloso⁵, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Clinica Universidad de Navarra, Pamplona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Clínica Universidad de Navarra, Pamplona, Spain
Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…
Abstract Number: 0759 • ACR Convergence 2024
Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media
Makoto Sugihara¹, Nobumasa Watanabe², Yuichiro Hara², Yasumasa Nishito³, Mai Kounoe⁴, Kazunari Sekiyama⁴, Eisuke Takamasu⁵, Naofumi Chinen⁶, Kota Shimada⁵ and Hideya Kawaji², ¹Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan, Higashimurayama-shi, Tokyo, Japan, ²Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ³Center for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁴Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁵Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, Fuchu-shi, Tokyo, Japan, ⁶Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tokyo, Japan, Tama-shi, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by inflammatory cell infiltration and destruction of the tunica media. In this study, we…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 1635 • ACR Convergence 2024
Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
Matthias Froehlich¹, Michael Gernert², Marc Schmalzing³, Patrick-Pascal Strunz⁴, Hanna Labinsky⁵, Thorsten A. Bley⁶ and Konstanze V. Guggenberger⁶, ¹Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ²Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ³University Hospital Wuerzburg, Würzburg, Germany, ⁴University hospital of Wuerzburg, Wuerzburg, Germany, ⁵University Hospital Würzburg, Wuerzburg, Germany, ⁶University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Imaging techniques such as magnetic resonance imaging (MRI) are a cornerstone for the diagnosis of giant cell arteritis (GCA). In the further course of…
Abstract Number: 2650 • ACR Convergence 2024
Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis
David Yang¹, Quy Cao², Fang Liu², Tara McWilliams², Ryan Rebello³, Madhura Tamhankar², Shubhasree Banerjee², Rui Liang², Robert Kurtz², Joshua Baker¹, Naomi Amudala², Zhaoyang Fan⁴, Jae Song², Peter Merkel¹, Jeffrey Morris² and Rennie Rhee¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³St Joseph’s Hospital and McMaster University, Hamilton, ON, Canada, ⁴University of Southern California, Los Angeles, CA
Background/Purpose: There is a need for measures of disease severity for giant cell arteritis (GCA), which may enable identification of high-risk subgroups (e.g., ophthalmic complications)…
Abstract Number: 0760 • ACR Convergence 2024
A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis
Kevin Chevalier¹, Léa Dionet¹, Paul Breillat¹, Margot Poux¹, Julien Dang¹, Benoit Terris², Patrick Bruneval³, Luc Mouthon⁴, Olivia Lenoir¹, Tharaux Pierre-Louis¹ and Benjamin Terrier⁵, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ³Department of Pathology, Hôpital Européen Georges Pompidou, GHU Paris Centre, AP-HP, Université Paris Cité, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large vessels. The role of macrophages and vascular smooth muscle cells (VSMC) appears to be…
Abstract Number: 1616 • ACR Convergence 2024
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Gaston Ariel Ghio¹, Marta Domínguez-Álvaro², Ricardo Blanco-Alonso³, Santos Castañeda⁴, Iñigo Hernández-Rodríguez⁵, Elisa Fernández-Fernández:⁶, Maite Silva-Diaz⁷, Joaquin María Belzunegui:⁸, Clara Moriano⁹, Julio Sánchez-Martín¹⁰, Javier Narvaez-García¹¹, Eva Galindez¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuán¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota L Iñiguez:¹⁷, Alicia García Dorta¹⁸, Clara Molina Almela¹⁹ and María Alcalde Villar:²⁰, and ARTESER Project Collaborative Group, ¹Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁷Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸H de Donostia, Donostia-San Sebasti, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Hospital Universitario de Cabueñes, Bilbao, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁸Rheumatologist, La Laguna, Spain, ¹⁹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁰Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Pablo Muñoz Martínez¹, Claudia Fernandez Ruiz², Elena Grau García³, Samuel Leal Rodriguez³, José Ivorra-Cortés⁴, Carmen Riesco Barcena⁵, Anderson Huaylla Quispe⁵, Laura Mas Sánchez⁶, Daniel Ramos Castro⁵, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado⁵ and Jose A Román-Ivorra⁹, ¹Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ²Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Rheumatology Department. HUP La Fe, Valencia, Spain, ⁶Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…
Abstract Number: 2651 • ACR Convergence 2024
Vasculitis Associated with VEXAS Syndrome
Megan Sullivan¹, Kambiz Kalantari², Carolyn Mead-Harvey³, Yael Kusne⁴, Mrinal Patnaik², Abhishek Mangaonkar², Ronald Go², Daniel Montes², Kaaren Reichard², Horatiu Olteanu², Melanie Bois², Alexander Hines², Julio Sartori-Valinotti⁵, Kenneth Warrington² and Matthew Koster², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic, Rohester, MN
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
Abstract Number: 0761 • ACR Convergence 2024
An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis
Ioannis Koulas¹, Nikolaos Tsaftaridis², Ivana Ilic³, Jack Jnani⁴, Alex Spyropoulos¹ and Lara El Khoury⁵, ¹Feinstein Institutes for Medical Research/Northwell Health, Manhasset, ²Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, ³Northwell, Brooklyn, NY, ⁴Department of Medicine/Northwell Health, Manhasset, ⁵Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 1638 • ACR Convergence 2024
Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis
Katarina Kmetova¹, Emily Chong², NaveenKumar Somanathapura K³, Kavya Sugur², Lyndsay Kluge², Srilakshmi Yalavarthi³, Julia Ford³, Ora Singer⁴ and Yu Zuo³, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann arbor, Ann arbor, MI, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally…
Abstract Number: 2652 • ACR Convergence 2024
Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study
Geoffroy Peyrac¹, Natalie Lomba Goncalves¹, Aïcha Kante², Patrice Cacoub³, Karim Sacré⁴, David Saadoun⁵, Thomas Papo⁴, Jean-François Alexandra⁶, Valentin Pagis⁷, Venceslas Bourdin¹, Pascal Richette⁸, Arnaud Vanjak⁹, Augustin Latourte¹⁰, Dikélélé Elessa⁷, William Bigot¹, Ruxandra burlacu⁷, Karine Champion¹, Blanca Amador Borrero⁷, Amanda Lopes¹, Audrey Depond⁷, Peggy Reiner¹¹, Homa Adle-Biassette¹², Aude Couturier¹³, Philippe Bonnin¹⁴, Alexandre Boutigny¹⁵, Frédéric Paycha¹⁶, Anne Couvelard¹⁷, Alexis Régent¹⁸, Benjamin Chaigne¹⁹, Yann Nguyen²⁰, Agnès lefort²⁰, Olivier Bory²¹, Elisabeth Aslangul²², stephane mouly¹, Damien Sène¹, Viet-Thi Tran²³ and Cloé Comarmond¹, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ²Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ³Sorbonne Université, Paris, ⁴Université Paris Cité, Paris, France, ⁵Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, ⁶INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, ⁸Lariboisière Hospital, Paris, France, ⁹Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁰AP-HP, Paris, France, ¹¹Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹²Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹³Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁴Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ¹⁵Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁶Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, ¹⁷Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, ²⁰Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, ²¹Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, ²²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ²³Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France
Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
Abstract Number: 1618 • ACR Convergence 2024
Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
Vivekanand Tiwari¹, chih fang², Emily Campbell³, Katherine loomba², Nisha Khubchandani², shikha shah² and William Rigby⁴, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth Health, Lebanon, NH, ⁴Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions that often co-occur.1 Approximately half of all patients with GCA experience PMR…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].